About This Page
This is a clinician-written, evidence-based summary aligned to the 2026 MLA Content Map. It is intended for medical students and junior doctors preparing for the UKMLA. Always cross-reference with NICE guidance, local protocols, and clinical judgement.
Key points
- SJS <10% BSA, overlap 10-30%, TEN >30%. Mortality: SJS ~5%, TEN ~30%
- Usually drug-induced (>80%): allopurinol, carbamazepine, lamotrigine, phenytoin, sulfonamides, NSAIDs
- Prodrome then dusky macules, sheet-like epidermal detachment, mucosal erosions (>90%)
- Nikolsky sign POSITIVE: skin shears off with lateral pressure
- EMERGENCY: STOP causative drug immediately. Burns unit/ICU. Supportive care
Overview
SJS and TEN are a spectrum of severe mucocutaneous reactions with widespread keratinocyte apoptosis and epidermal detachment. >80% drug-induced (1-3 weeks after initiation). Pathogenesis involves cytotoxic T cells and NK cells causing apoptosis via Fas-FasL and granulysin. Mucous membrane involvement in >90%. A dermatological emergency with significant mortality.
Epidemiology
SJS ~1-6 per million/year; TEN ~0.4-1.2 per million/year. 100x higher in HIV-positive. Common causative drugs: allopurinol, aromatic anticonvulsants, sulfonamides, NSAIDs, nevirapine. Pharmacogenomic risk: HLA-B*5801 (allopurinol), HLA-B*1502 (carbamazepine in SE Asian populations).
Clinical Features
Symptoms
Prodrome: fever, malaise, sore throat 1-3 days before rash
Painful burning skin — widespread
Oral erosions, ocular pain, genital ulceration (mucosal involvement >90%)
Recent new medication 1-3 weeks prior
Signs
Widespread dusky macules and atypical targets with necrotic centres
Sheet-like epidermal detachment — skin peels leaving raw dermis
Nikolsky sign POSITIVE
Haemorrhagic lip crusting, bilateral purulent conjunctivitis
Investigations
First-line
Drug historyIdentify causative agent (started 1-3 weeks prior)
Skin biopsyFull-thickness epidermal necrosis with subepidermal split
Second-line
SCORTEN scorePrognostic: age >40, malignancy, HR >120, BSA >10%, urea >10, glucose >14, bicarb <20
BloodsFBC, U&E, LFT, glucose, bicarb, cultures
Specialist
OphthalmologyUrgent — ocular involvement common, risk of permanent scarring
Management
BAD Guidelines on SJS/TEN1
STOP the drug
- IMMEDIATELY discontinue suspected drug — most important intervention
- Early withdrawal reduces mortality
2
Supportive care — burns unit/ICU
- Manage as burns: fluids, temperature, nutrition
- Non-adherent dressings, avoid debridement of attached epidermis
- Pain: often requires opioids
- Infection monitoring — sepsis is leading cause of death
3
Mucosal care
- Oral: mouthwashes, lip care, NG feeding if needed
- Ocular: URGENT ophthalmology — lubricants, daily slit lamp
- Genital: catheterisation if urethral involvement
4
Drug NEVER to be used again
- Absolute contraindication for life to causative drug class
Complications
- Mortality: SJS ~5%, TEN ~25-35%. Sepsis and MOF leading causes
- Ocular: Scarring, symblepharon, dry eyes, blindness — commonest long-term complication
- Mucosal strictures: Oesophageal, urethral
- PTSD/depression
UKMLA Exam Tips
- 1SJS <10%, overlap 10-30%, TEN >30% BSA
- 2Common drugs: Allopurinol, Carbamazepine, Lamotrigine, Sulfonamides (ACLS)
- 3Nikolsky positive = epidermis shears off — also seen in pemphigus vulgaris
- 4STOP the drug IMMEDIATELY — delay increases mortality
- 5SJS/TEN: full-thickness necrosis at dermo-epidermal junction. SSSS: superficial intra-epidermal
- 6Atypical targets (flat, 2-zone) in SJS/TEN. TRUE targets (3-zone) in erythema multiforme
- 7Urgent ophthalmology — ocular complications are most common long-term morbidity
Put your reading into practice
Topic-specific question practice is not linked for this article yet.
Choose UKMLA questions from the existing bank. General exam practice covers your selected topics; it is not filtered to this article. Your usual question-bank access applies.
Choose UKMLA practiceAfter your session, return to this section to revisit the reading and choose your next review.
Verified Sources & References
related resources
Save your place and choose what comes next
Dermatology · Article 18 of 25